.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,461,211

« Back to Dashboard

Claims for Patent: 8,461,211

Title:Use for budesonide and formoterol
Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
Inventor(s): Bauer; Carl-Axel (Lund, SE), Trofast; Jan (Lund, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:12/982,360
Patent Claims: 1. A method for treating a patient suffering from chronic obstructive pulmonary disease (COPD), the method comprising administering to the patient via inhalation a composition comprising formoterol fumarate dihydrate and budesonide.

2. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 1 to 50 .mu.g formoterol fumarate dihydrate and 45 to 2200 .mu.g budesonide.

3. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 3 to 30 .mu.g formoterol fumarate dihydrate and 45 to 2200 .mu.g budesonide.

4. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 4.5 or 9 .mu.g formoterol fumarate dihydrate.

5. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 80, 160, or 320 .mu.g budesonide.

6. The method of claim 1, wherein the composition is administered to the patient in unit doses, each unit dose delivering to the patient 4.5 .mu.g formoterol fumarate dihydrate and 80 or 160 .mu.g budesonide.

7. The method of claim 1, wherein the composition is administered to the patient in up to four unit doses per day, each unit dose delivering to the patient 4.5 .mu.g formoterol fumarate dihydrate and 160 .mu.g budesonide.

8. The method of claim 1, wherein the composition is administered to the patient in one or two unit doses per day, each unit dose delivering to the patient 9 .mu.g formoterol fumarate dihydrate and 320 .mu.g budesonide.

9. The method of claim 1, wherein the composition is in the form of a dry powder and is administered from a dry powder inhaler.

10. The method of claim 1, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler.

11. The method of claim 1, wherein the composition is administered via a nebulizer.

12. The method of claim 1, wherein the formoterol fumarate dihydrate and budesonide are in the form of particles of a size less than 10 .mu.m.

13. The method of claim 2, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler.

14. The method of claim 3, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler.

15. The method of claim 4, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler.

16. The method of claim 5, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler.

17. The method of claim 6, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler.

18. The method of claim 7, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler.

19. The method of claim 8, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler.

20. The method of claim 12, wherein the composition comprises a propellant and is administered from a pressurized metered dose inhaler.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc